Horner has more than 40 years of industry experience gained with biotech and big pharma companies. He was most recently ceo of Prestwick Pharmaceuticals, a private CNS company that was sold to Biovail Corporation and Ovation Pharmaceuticals in 2008.
Prior to joining Prestwick, Horner was ceo of Vicuron, a publicly listed anti-infectives company that was sold to Pfizer for US$1.9bn in 2005. He also worked for Ligand Pharmaceuticals following a career at Abbott Laboratories where rose to president of the company’s business in Canada.
‘I have been attracted to this opportunity by the company’s rich pipeline of clinical and pre-clinical drug candidates focused on dermatological indications, its deep understanding of the science behind a number of serious skin disorders, as well as its technology platform with broad utility. I am sure that from this strong base we will be able to generate significant value for Creabilis shareholders,’ said Horner.
Dermatology specialist appoints chairman
George Horner joins Creabilis of Luxembourg
You may also like
Pharmaceutical
Enanta Pharma files patent infringement suit against Pfizer in the Unified Patent Court of the EU
The company is seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the 265 Patent) in the manufacture, use and sale of Pfizer’s COVID-19 antiviral, Paxlovid (nirmatrelvir tablets; ritonavir tablets)
Regulatory
The foundations of pharmaceutical compliance for beginners
Whether you’re stepping into the pharmaceutical industry for the first time or pivoting into a compliance or quality assurance role after years of experience, mastering the fundamentals of quality and regulatory compliance is vital to your success—and to the success of your organisation
Manufacturing
WLS introduces PR-12 and PR-24 plunger rod insertion and labelling systems
By improving reliability and streamlining production, the PR-12 and PR-24 help pharmaceutical manufacturers and contract packers protect product quality and reduce waste while maximising operational efficiencies
Pharmaceutical
Azelis strengthens its footprint in Italy with the acquisition of Azienda Chimica e Farmaceutica (‘ACEF’)
Azelis is pleased to announce that it has acquired 100% of the shares of Azienda Chimica e Farmaceutica (‘ACEF’), a distributor of speciality raw materials and ingredients for the cosmetic, nutraceutical, galenic and pharma industries in Italy